The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
about
The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for humNeoadjuvant therapy for pancreas cancer: past lessons and future therapiesSurvival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis.Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens.Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer.Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.S-1-Based versus capecitabine-based preoperative chemoradiotherapy in the treatment of locally advanced rectal cancer: a matched-pair analysis.Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreasS-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysisSequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells.Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis.Targeted therapy in gastroesophageal cancers: past, present and future.Tailor-made chemotherapy for non-small cell lung cancer patients.Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancerPhase-I trial of oral fluoropyrimidine anticancer agent (S-1) with concurrent radiotherapy in patients with unresectable pancreatic cancer.Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer.Molecular markers for gastric adenocarcinoma: an update.Phase II study of gemcitabine plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy.Capecitabine in advanced gastric cancer.Chemotherapy for advanced gastric cancer: review of global and Japanese status.5-Fluorouracil: mechanisms of resistance and reversal strategies.Analysis of feasibility and toxicity of concurrent chemoradiotherapy with S-1 for locally advanced squamous cell carcinoma of the head and neck in elderly cases and/or cases with comorbidity.A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.Lipophilic prodrugs and formulations of conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer.Emerging drugs for cervical cancer.Strategies of targeting oral drug delivery systems to the colon and their potential use for the treatment of colorectal cancer.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.New pharmacotherapy options for cervical cancer.Emerging drugs for the treatment of cervical cancer.Advances in oral delivery of anti-cancer prodrugs.Feasibility of an interactive electronic self-report tool for oral cancer therapy in an outpatient setting.E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models.Capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOXs) in advanced gastric cancer: meta-analysis of randomized controlled trials.Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer.Adenosquamous carcinoma of maxillary sinus: case showing complete response to S-1.Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck.S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma.How long should we continue S-1 as adjuvant chemotherapy for squamous cell carcinoma of the head and neck?
P2860
Q24633301-E669A38A-C409-4525-B219-A3C2B2BE8D5AQ27004292-82935132-9C5A-4190-8271-AF7304D15AB5Q33416158-4625A034-6A29-4268-ADEB-5BEFEF32D2F8Q33439361-FFF8BD82-7731-40AE-A37F-9D3F7DF339B8Q33884698-73316AFE-849C-46D1-BCAC-F953760F97B6Q34074410-2C5829E1-68E7-4B79-82D2-1154ABAA4EE4Q34121751-73BF17FF-9F65-4AEF-99A9-119EB911E244Q34449812-CAF121AF-85D2-4D33-BBC7-B73D66589493Q34897322-D7BDF363-A295-48F4-8402-35C02CC91B73Q35083334-8134C8FB-9F94-4743-835A-F9212137467EQ35145128-E5EEA1DA-5B47-48AE-8850-2BC06D575EEEQ36103180-1E34DF6D-A968-4683-88FB-E4E41085689EQ36294579-A5501105-DA22-43B9-AD65-4B5EB4123EB9Q36430761-2AB8984C-5EBC-4C4B-8695-BF0D2A97195AQ36609741-BDFF4AE4-E68D-4343-8C63-97D338E019E4Q36610363-4E7F6B76-6F99-4E51-9A50-BA3F6E4E00F1Q36615451-A9FA4924-52FC-42E8-A6CC-83F5593EA8C7Q36677268-4D22043B-65B3-46B2-B497-FBF7B1B6927FQ36915011-F88498DA-DC01-4CE6-8721-6EDC1431BE8BQ36979346-F1527F2D-5FD9-4103-A0FF-05A2ECEB6989Q37076553-6712C93C-0A63-437E-B6E2-8A629E77E1B0Q37270356-DF709255-0C68-48E7-91C8-1567967FA38EQ37308769-9E41D30B-28EF-4235-BBF5-9ED57122FAA0Q37889959-5E66469F-F431-475D-A6AC-1D3D1BE6E8FCQ37963493-E9909341-7ABE-45FD-93E8-DBFDE0162350Q38005222-6F3F45F9-77F4-45AF-AFB3-DB4F71490986Q38017299-13B9794B-5F7F-494A-A1EC-0545F3FABD9CQ38082728-67ABA13D-90E4-47B6-888F-48D9D407527EQ38160897-12C2283A-9114-4D96-BA3B-DC8844B5C439Q38314157-847B9536-D7F5-40B0-B57E-5E84F585579DQ38862820-1B2160AB-68F9-448A-A037-2C7B2AEFC475Q39879882-BBAEC1D2-7361-4F0D-AAF3-9AB032551270Q40045957-0AD48764-79A2-4CE4-96FE-B320033F830FQ41186022-1C2A18C6-35AF-4FED-AF90-B77DBDC09559Q42705196-6A2092FA-3E2B-4CBB-9161-502D444380E6Q46157648-5085803D-BB31-4379-A85E-5FE2F951EA07Q46875032-47B616F4-A91A-47DA-9E7C-68E3DC4522C5Q49860695-D1D85A13-C78D-4058-A2D9-DF1E139A5891Q52884293-6D7CC94D-08AE-47EF-87CC-BF0657646A54Q53494556-7E05D1DB-C539-4229-BBA4-2C20C37F9A44
P2860
The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The modulated oral fluoropyrim ...... cancer and other solid tumors.
@ast
The modulated oral fluoropyrim ...... cancer and other solid tumors.
@en
The modulated oral fluoropyrim ...... cancer and other solid tumors.
@nl
type
label
The modulated oral fluoropyrim ...... cancer and other solid tumors.
@ast
The modulated oral fluoropyrim ...... cancer and other solid tumors.
@en
The modulated oral fluoropyrim ...... cancer and other solid tumors.
@nl
prefLabel
The modulated oral fluoropyrim ...... cancer and other solid tumors.
@ast
The modulated oral fluoropyrim ...... cancer and other solid tumors.
@en
The modulated oral fluoropyrim ...... cancer and other solid tumors.
@nl
P1433
P1476
The modulated oral fluoropyrim ...... cancer and other solid tumors.
@en
P304
P356
10.1097/00001813-200402000-00001
P577
2004-02-01T00:00:00Z